NCT07467772 2026-04-21
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
11 trialsNCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT05963997 2026-03-23
SUMIT-ELA
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT07222215 2026-01-22
CAPELA
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT05618613 2025-05-09
ELONA
Context Therapeutics Inc.
Phase 1/2 Terminated
NCT06938711 2025-04-22
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Context Therapeutics Inc.
Phase 1/2 Withdrawn
NCT06126575 2024-11-19
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
Stemline Therapeutics, Inc.
Phase 1 Completed
NCT02650817 2022-08-18
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Completed